Completed PHASE1 INTERVENTIONAL 4-arm NCT01747616

Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses

Sponsor: Croma-Pharma GmbH

Interventions Chitosan-N-acetylcysteine eye drops (concentration of 0.1%) Physiological saline solution

Updated 5 times since 2017 Last updated: Dec 10, 2012 Started: Jul 31, 2011 Primary completion: Nov 30, 2011 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01747616, this PHASE1 trial focuses on Dry Eye Syndrome and remains completed. Sponsored by Croma-Pharma GmbH, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Croma-Pharma GmbH
Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria